QureTech Bio

Quretech Bio - defeats bacterial virulence

Since World War II, antibiotics have been the most effective factor in longevity and population expansion. Today, loss of effective antibiotics threatens our medical institutions – antibiotic resistance is a serious problem already or will be within the decade. Doctors, in the US and UK, have reported that they now have less than a handful effective antibiotics for some pathogens. In the EU alone, infections with multidrug resistant bacteria cause around 25,000 deaths each year and the associated economic burden is immense. Still in today’s world, more infants and children are dying from pneumonia than from malaria.

QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. The global market for antibiotics is estimated at USD 38 billion with USA, Europe and Japan representing 50%. The cost of antibiotic resistance to medical communities in the EU alone is conservatively estimated to be €1.5 billion and the availability of new targeted antibiotics of this type would generate significant cost savings for healthcare systems.

New types of antibiotics to tackle resistant bacteria are urgently needed, yet there is an almost empty drug pipeline with few early stage drugs under development. Scientific and industrial communities must develop new antibiotic drugs, and there must be a drive towards developing novel antibiotics with alternative modes of action.


Current projects

Fredrik Almqvist, Chief Chemist at QureTech Bio, till enter the stage for a TEDxUmeå on May 3rd ... See MoreSee Less

Our next speaker are working on turning the tide of antimicrobial resistance. A Warm welcome to Fredrik Almqvist! Who am I? I’m a Professor in Organic Chemistry at the Department of Chemistry at Umeå University. After earning a PhD at Lund University and a postdoctoral stay at Washington University in St. Louis, I returned to Umeå University where I have established a research group with a common overall goal to understand bacterial pathogenesis and develop new ways to combat antimicrobial resistance. In order to improve our chances of reaching our goals, we have been fortunate to collaborate with renowned researchers with complementary expertise in areas such as molecular biology, clinical microbiology, structural biology and biophysics. In addition to being a scientist and lecturer at the University, I’m also an entrepreneur and have founded two companies – SpinChem AB and QureTech Bio AB. Why listen to me? Due to the spread of genes contributing to antibiotic resistance, the world is rapidly approaching the post-antibiotic era, complicating simple surgery and cancer treatments. Although it is estimated that 700,000 people die every year of bacteria that are resistant to one or several antibiotics, only a few truly new antibiotics have been introduced to the market during the last decades. Hans Rosling also stressed the need for new alternatives to combat antibiotic resistance bacteria and claimed this problem to be equal or even tougher than global climate change. I will highlight some new promising approaches to tackle this global challenge.

View on Facebook

Viktigt meddelande från Läkare Utan Gränser. ... See MoreSee Less

Du dör inte av ett litet sår i Sverige idag. Men nu är världen på väg att färdas 70 år tillbaka i tiden. Vi vill berätta en skräckhistoria - från verkliga livet. Häng med!

View on Facebook

QureTech Bio stands up to the challenge! ... See MoreSee Less

Each year on March 24, World TB Day is recognized to mark Dr. Robert Koch’s announcement in 1882 of discovering Mycobacterium tuberculosis, the bacillus that causes tuberculosis (TB). CDC joins our global partners in supporting this year’s theme, “Unite to End TB.” Learn more: bit.ly/2nYMIoR.

View on Facebook